
Claims

1. A compound of the formula



(I),

in which

n represents the number 0, 1, 2 or 3,

R^1 represents hydrogen, methyl, ethyl, n-propyl or isopropyl,

R^2 represents linear or branched PEG 20kDa to 80kDa endcapped with a methoxy-group,

or one of the salts thereof, solvates thereof or the solvates of salts thereof.

2. A compound as claimed in claim 1, characterized in that

n represents the number 1 or 2,

R^1 represents hydrogen or methyl,

R^2 represents linear PEG 40kDa endcapped with a methoxy-group.

3. A compound as claimed in either of claims 1 and 2, characterized in that


n represents the number 1 or 2,

R^1 represents hydrogen,

R^2 represents linear PEG 40kDa endcapped with a methoxy-group.

4. A process for preparing a compound of the formula (I) or one of the salts thereof, solvates thereof or the solvates of salts thereof as claimed in claim 1, characterized in that a

compound of the formula (II)




(II),

in which

n and R^1 are each as defined in claim 1,

is reacted with a compound of the formula (III)



(III),

in which

R^2 is as defined in claim 1.

5. A compound as claimed in any of claims 1 to 3 for treatment and/or prevention of diseases.

6. The use of a compound as claimed in any of claims 1 to 3 for producing a medicament for treatment and/or prevention of diseases.

7. The use of a compound as claimed in any of claims 1 to 3 for producing a medicament for treatment and/or prevention of cardiovascular, edematous and/or inflammatory disorders.

8. A medicament comprising a compound as claimed in any of claims 1 to 3 in combination with an inert nontoxic pharmaceutically suitable excipient.

9. A medicament comprising a compound as claimed in any of claims 1 to 3 in combination with a further active ingredient.

10. The medicament as claimed in claim 8 or 9 for treatment and/or prevention of


cardiovascular, edematous and/or inflammatory disorders.

11. The use of a compound as claimed in any of claims 1 to 3 for producing a medicament for treatment and/or prevention of heart failure, coronary heart disease, ischemic and/or hemorrhagic stroke, hypertension, pulmonary hypertension, peripheral arterial occlusive disease, pre-eclampsia, chronic obstructive pulmonary disease, asthma, acute and/or chronic pulmonary edema, allergic alveolitis and/or pneumonitis due to inhaled organic dust and particles of fungal, actinomycetic or other origin, and/or acute chemical bronchitis, acute and/or chronic chemical pulmonary edema, neurogenic pulmonary edema, acute and/or chronic pulmonary manifestations due to radiation, acute and/or chronic interstitial lung disorders, acute lung injury/acute respiratory distress syndrome (ALI/ARDS) in adult or child including newborn, ALI/ARDS secondary to pneumonia and sepsis, aspiration pneumonia and ALI/ARDS secondary to aspiration, ALI/ARDS secondary to smoke gas inhalation, transfusion-related acute lung injury (TRALI), ALI/ARDS and/or acute pulmonary insufficiency following surgery, trauma and/or burns, and/or ventilator induced lung injury (VILI), lung injury following meconium aspiration, pulmonary fibrosis, mountain sickness, chronic kidney diseases, glomerulonephritis, acute kidney injury, cardiorenal syndrome, lymphedema, inflammatory bowel disease, sepsis, septic shock, systemic inflammatory response syndrome (SIRS) of non-infectious origin, anaphylactic shock, inflammatory bowel disease and/or urticaria.

12. A compound as defined in any of claims 1 to 3 for use in a process for treatment and/or prevention of cardiovascular, edematous and/or inflammatory disorders.

CLAIMS

1. A compound of the formula



(I),

in which

n represents the number 0, 1, 2 or 3,

R^1 represents hydrogen, methyl, ethyl, n-propyl or isopropyl,

R^2 represents linear or branched PEG 20kDa to 80kDa endcapped with a methoxy-group,

or one of the salts thereof, solvates thereof or the solvates of salts thereof.

2. A compound as claimed in claim 1, **characterized in that**

n represents the number 1 or 2,

R^1 represents hydrogen or methyl,

R^2 represents linear PEG 40kDa endcapped with a methoxy-group.


3. A compound as claimed in either of claims 1 and 2, **characterized in that**

n represents the number 1 or 2,

R^1 represents hydrogen,

R^2 represents linear PEG 40kDa endcapped with a methoxy-group.

4. A process for preparing a compound of the formula (I) or one of the salts thereof, solvates thereof or the solvates of salts thereof as claimed in claim 1, **characterized in that** a compound of the formula (II)




(II),

in which

n and R^1 are each as defined in claim 1,

is reacted with a compound of the formula (III)



(III),

in which

R^2 is as defined in claim 1.

5. A compound as claimed in any of claims 1 to 3 for use in the treatment and/or prevention of diseases.

6. The use of a compound as claimed in any of claims 1 to 3 for producing a medicament for treatment and/or prevention of diseases.

7. The use of a compound as claimed in any of claims 1 to 3 for producing a medicament for treatment and/or prevention of cardiovascular, edematous and/or inflammatory disorders.

8. A medicament comprising a compound as claimed in any of claims 1 to 3 in combination with an inert nontoxic pharmaceutically suitable excipient.

9. A medicament comprising a compound as claimed in any of claims 1 to 3 in combination with a further active ingredient.

10. The medicament as claimed in claim 8 or 9 for use in the treatment and/or prevention of cardiovascular, edematous and/or inflammatory disorders.

11. The use of a compound as claimed in any of claims 1 to 3 for producing a medicament for treatment and/or prevention of heart failure, coronary heart disease, ischemic and/or hemorrhagic stroke, hypertension, pulmonary hypertension, peripheral arterial occlusive disease, pre-eclampsia, chronic obstructive pulmonary disease, asthma, acute and/or chronic pulmonary edema, allergic alveolitis and/or pneumonitis due to inhaled organic dust and particles of fungal, actinomycetic or other origin, and/or acute chemical bronchitis, acute and/or chronic chemical pulmonary edema, neurogenic pulmonary edema, acute and/or chronic pulmonary manifestations due to radiation, acute and/or chronic interstitial lung disorders, acute lung injury/acute respiratory distress syndrome (ALI/ARDS) in adult or child including newborn, ALI/ARDS secondary to pneumonia and sepsis, aspiration pneumonia and ALI/ARDS secondary to aspiration, ALI/ARDS secondary to smoke gas inhalation, transfusion-related acute lung injury (TRALI), ALI/ARDS and/or acute pulmonary insufficiency following surgery, trauma and/or burns, and/or ventilator induced lung injury (VILI), lung injury following meconium aspiration, pulmonary fibrosis, mountain sickness, chronic kidney diseases, glomerulonephritis, acute kidney injury, cardiorenal syndrome, lymphedema, inflammatory bowel disease, sepsis, septic shock, systemic inflammatory response syndrome (SIRS) of non-infectious origin, anaphylactic shock, inflammatory bowel disease and/or urticaria.

12. A compound as defined in any of claims 1 to 3 for use in a process for treatment and/or prevention of cardiovascular, edematous and/or inflammatory disorders.